• Sophie Reed, Michele Pansini, Charlie Diamond, Amitava Banerjee, Helena Thomaides Brears, and Onima Chowdhury.
• Oxford University Hospitals' NHS Foundation Trust, Oxford, UK; Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK.
• Eur. J. Intern. Med. 2024 Oct 1; 128: 150152150-152.

BackgroundDuring the COVID-19 pandemic individuals with all blood cancers were classified as clinically vulnerable and at high risk of complications and death. Our study sought to determine if individuals with specific blood cancers were at a heightened risk of longer term organ impairment, secondary to SARS-CoV-2 infection.MethodsWe set up a prospective observational study, utilising quantitative multi-parametric MRI to determine organ health over time in patients with specific blood cancers who had recovered from COVID-19.ResultsMulti-organ abnormality was more prevalent in blood cancer patients than in healthy controls (42 % vs 6 % p < 0.001) but comparable to the long COVID controls (42 % vs 33 %, p > 0.05). At 6 month follow up scans, organ abnormalities persisted in most individuals with blood cancer (71 % ≥1 organ and 52 % multi-organ).ConclusionA multi-organ MRI platform offers the capacity to accurately evaluate organ health dynamically in blood cancers and detect asymptomatic organ impairment. The application of multi-organ MRI could aid early detection and longitudinal monitoring of organ impairment, potentially guiding more personalised treatment strategies and improving clinical outcomes in many rare diseases.Copyright © 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

37 keywords...

hide…